European Archives - Page 707 of 1303 - European Medical Journal

Aficamten: A New Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy

REDWOOD-HCM was a multicentre, randomised, placebo-controlled, double-blind, dose-finding clinical trial of aficamten in patients with symptomatic oHCM on background medical therapy.

Automated Echocardiography Analysis: Expanding Access and Saving Time

December marks the launch of Us2.ai’s automated cardiac analysis platform1 as a cloud-based service on the EchoNous Kosmos device…

Identifying Common Biomarkers Between COVID-19 and Commonly Associated Comorbidities

The recent COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, since its…

Current Therapy for Homozygous Familial Hypercholesterolaemia

Homozygous familial hypercholesterolaemia (HoFH) is a rare and aggressive disorder, resulting from the inheritance of mutations in the two alleles of genes regulating the low-density lipoprotein receptor (LDL-R) function.

Risk Factors and Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis: An Update

The therapeutic technique of endoscopic retrograde cholangiopancreatography (ERCP) has evolved as a therapeutic endoscopic technique for…

Cefixime-Induced Hepatitis: A Case Report and Review of Literature

Cephalosporins, a family of bactericidal antibiotics, have side effects like penicillin due to the similarity in their basic structure…

The biotech boom: fad or forever?

Biotechs have stood as agile hubs for drug discovery, but now they are being coveted by investors.

Standing out in a crowd of digital content

The amount of digital content being created for healthcare professionals has grown exponentially. Medical affairs teams must find a way to cut through the noise with their communications

A cautionary tale of digital transformation

As the pharmaceutical industry embraces digital transformation, new technologies have the potential to sink or swim. How can the industry ensure it’s backing the most effective innovations and not getting stuck in dead ends?

The future of pharmaceutical sales

The COVID-19 pandemic has reshaped pharmaceutical sales, moving from face-to-face to predominantly digital interactions. How can sales reps adapt to multichannel approaches and enhance performance amidst this shift in sales training and team dynamics?